LOXO-101 1223403-58-4

Hōʻike Pōkole:

Ka inoa o API Hōʻike Mea Hoʻohou Hou Palapala Hoʻoholo Patent (The US)
LOXO-101 1223403-58-4 Laau ʻona Oncology Loxo Oncology ʻOkakopa 21,2029

ʻIke kikoʻī

Nā huahana huahana

ʻIkepili Huahana

Papa kāʻei kua

IC50: pae nanomolar haʻahaʻa no ka pāpā ʻana i nā lālā ʻohana TRK āpau

ʻO LOXO-101 kahi mea hoʻoiho tropicyosin kinases (TRK) mea kāohi.

ʻO kaʻohana TRK o nā mea loaʻa nā neurotrophin a me kā lākou mau ligands neurotrophin e hoʻoponopono i ka ulu ʻana o ka neuron, ka ʻokoʻa a me ke ola

In vitro: I ke aʻo ʻana ma mua, loiloi ʻia ʻo LOXO-101 no ka pāpā ʻana o ka ʻenima kinase i waho i ka pahuhopu o nā kinase non-TRK ma kahi kūmole o ka 1000 nM a me ka ATP no ka Km. Ua hōʻike ʻia nā hopena i loaʻa ʻo LOXO-101 i ʻoi aku ma mua o 50% kaohi no hoʻokahi non-TRK kinase, ʻo ia ʻo TNK2 me IC50 o 576 nM. Eia kekahi, ʻaʻohe pili kūpono hERG a i ʻole nānā QT hoʻolōʻihi ʻia [1].

In vivo: ʻIke ʻia ka ʻike holoholona i hiki i ka LOXO-101 ke kāohi i ka ulu ulu vivo. Ua mālama waha ʻia nā ʻiole nude Athymic me nā hunaola KM12 me LOXO-101 i kēlā me kēia lā no 2 mau pule, a ua mālama ʻia ke kaohi ʻana o ka tumo pili i ka lāʻau, e hōʻike ana i ka hiki o LOXO-101 ke kāohi i ka ulu ulu ulu vivo [1].

Hoʻokolohua hoʻokolohua: Ua mālama ʻia kahi mahele multicenter I i hoʻopaʻa ʻia i nā maʻi me nā tumors paʻa holomua (ClinicalTrials.gov no. NCT02122913) i ka makahiki 2014 e loiloi i ka palekana a me PK o LOXO-101. Hoʻokomo ʻia nā mea maʻi i hoʻokahi a i ʻole ʻelua mau lā i kēlā me kēia lā no 28 mau lā o ka hana mau ʻana i nā cohorts e piʻi nei. Hōʻike ka PK mua a me ka ʻikepili palekana i nā pae plasma manuahi o LOXO-101 ma nā kikoʻī e pili ana i ka biologically e kāohi i nā oncogenes TRK. I kēia noi ʻana, ua hōʻike ka mea maʻi mua a hoʻokahi wale nō TRK fusion a me ka wikiwiki o ke kūpikipiki maʻi ʻōniu i ʻike ʻia me ka mālama ʻana iā LOXO-101 [1].

Kuhikuhi:
[1] Doebele RC et al. ʻO kahi Oncogenic NTRK Fusion i kahi mea maʻi me ka Sarcoma Soft-Tissue me ka pane i ka Tropomyosin-pili Kinase Inhibitor LOXO-101. Cancer Discov. 2015 ʻOkakopa; 5 (10): 1049-57.

 

Wehewehe

 

ʻO Larotrectinib (LOXO-101) he mea hoʻokūkū waha ATP, mea hōʻoki koho o nā kinase ʻohana e pili ana i ka tropomyosin (TRK), me nā nanomolar haʻahaʻa 50% hoʻoikaika kūwaho e kūʻē i nā isoforms ʻekolu (TRKA, B, a me C).

 

Hoʻokolohua Lapaʻau

Helu NCT Kākoʻo Kūlana Lā Hoʻomaka

ʻĀpana

NCT03025360 Bayer Tumors Harboring NTRK Hoʻohui  

NCT02637687 Bayer Pākuʻi Tumors Harbour NTRK Fusion Kekemapa 16, 2015

Papa 1 | Papa 2

NCT02122913 Bayer Pākuʻi Tumors Harbour NTRK Fusion 4 Mei 2014

Papa 1

NCT03213704 Ke Keʻena Luna ʻInikena National (NCI) ʻO Neoplasm Mākaʻi Mākaʻikaʻi Advanced | Ependymoma Kūʻai Hou | Ewing Sarcoma + Peripheral Primitive Neuroectodermal Tumor | ʻO Glioma hou | Hepatoblastoma hou | Recurrent Langerhans Cell Histiocytosis | Hoʻohui Malignant Germ Cell Tumor | Recurrent Malignant Grooma | Recopent Malignant | Non-Hodgkin Lymphoma | ʻO ka hou Osteosarcoma | ʻO Rhabdoid Tumor kū hou | ʻO Rhabdomyosarcoma kū hou | ʻO Recomment Soft Tissue Sarcoma | Refractory Ependymoma | Refractory Ewing Sarcoma + Peripheral Primitive Neuroectodermal Tumor | Refractory Glioma Reactory Malignant Glioma | Refractory Malignant Solid Neoplasm | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma | Refractory Osteosarcoma | Refractory Primary Central Nervous System Neoplasm | Refractory Rhabdoid Tumor | Refractory Rhabdomyosarcoma | Wilms Tumor Lulai 24, 2017

Kau 2

NCT02465060 Ke Keʻena Luna ʻInikena National (NCI) ʻO Advanced Neignlas Solid Neoplasm | ʻO ka maʻi ʻaʻai | ʻO ka maʻi kanulau | ʻO ka maʻi maʻi | ʻOihana kāne | ʻO ka maʻi maʻi maʻi | Endometrial Carcinoma | ʻO Esophageal Carcinoma | ʻO Gastric Carcinoma | Glioma | ʻO ke poʻo poʻo a me ka ʻāʻī maʻi | Ka maʻi kīhāhā | Līkū pūhū | Malignant Uterine Neoplasm | Melanoma | Ovarian Carcinoma | Pancreatic Car cancer | Kāleka Glioma | Ke poʻo hou a me ka maʻi kanikau | Ka maʻi kanesa kū hou | Ka maʻi ʻaʻa maʻi | Lymphoma kū hou | Ka neʻe hou malignant neoplasm | Melanoma kū hou | Ka maʻi kanesa Ovarian | Ka maʻi kanesa hou | Ka maʻi kanesa maʻi | | ʻO ka maʻi kanesa o ka ʻili hou | Kelepona thyroid hou Ka maʻi ʻaʻai | Ka maʻi ʻaʻai Uterine Corpus maʻi ʻaʻai | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma | ʻIli maʻi ʻaʻai | ʻO ka thyroid gland carcinoma | kōpū maʻi ʻōpū ʻAukake 12, 2015

Kau 2

NCT03834961 ʻOihana Oncology Children | National Cancer Institute (NCI) ʻO Neoplasm Pūnaewele Nervous Waena | Fibrosarcoma Infantile | Leukemia Acute Hou | ʻO Leukemia Refractory Acute | Neoplasm paʻa Kepakemapa 18, 2019

Kau 2

NCT04142437 Bayer ʻO ka pae kiʻekiʻe a i ʻole Metastatic Solid Tumor Harbouring a NTRK Gene Fusion ʻApelila 3, 2020

NCT03155620 Ke Keʻena Luna ʻInikena National (NCI) Advanced Malignant Solid Neoplasm | Ann Arbor Stage III Non-Hodgkin Lymphoma | Ann Arbor Stage IV Non-Hodgkin Lymphoma | Histiocytic Sarcoma | Juvenile Xanthogranuloma | Langerhans Cell Histiocytosis | Malignant Glioma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Goma | Recurrent Epoma ʻO Hepatoblastoma hou hou | ʻO Langerhans Cell Histiocytosis Pūnaewele | ʻO ka Neoplasm Maʻemaʻe Malignant | Kūleʻa Malignant Solid Neoplasm | ʻO Medulloblastoma hou | ʻO Neuroblastoma hou | ʻO Non-Hodgkin Lymphoma | ʻO Osteosarcoma Pūnaewele Nūhou Neuro | | ʻO Recomment Soft Tissue Sarcoma | Refractory Ewing Sarcoma | Refractory Glioma | Refractory Hepatoblastoma | Refractory Langerhans Cell Histiocytosis | Refractory Malignant Germ Cell Tumor | Refractory Malignant Solid Neoplasm | Refractory Medulloblastoma | Refractory Refractory | ctory Peripheral Primitive Neuroectodermal Tumor | Refractory Primary Central Nervous System Neoplasm | Refractory Rhabdoid Tumor | Refractory Rhabdomyosarcoma | Rhabdoid Tumor | Stage III Osteosarcoma AJCC v7 | Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Osteoscomue | Kahua IVA Osteosarcoma AJCC v7 | kahua IVB Osteosarcoma AJCC v7 | Wilms Tumor Lulai 24, 2017

Kau 2

ʻAno kemika

LOXO-101 1223403-58-4

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

KA MANAWAI ANA

Quality management1

Palapala Noi 18 Nā papahana loiloi e like me ka Consistency i ʻae ʻia 4, a 6 ke ʻae ʻia nei nā papahana.

Quality management2

Ua hoʻokumu ʻia ka ʻōnaehana hoʻokele kūlana kiʻekiʻe kiʻekiʻe loa no ke kūʻai aku.

Quality management3

Holo ka nānā ʻana i ka maikaʻi ma waena o ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic. 

Quality management4

Kākoʻo ka ʻoihana Hoʻokele ʻoihana ʻoihana i nā koi maikaʻi i ka wā o ka noi a me ke kau inoa.

MANAGEMENT HUA

cpf5
cpf6

Kōleka Packaging ʻōmole Korea

cpf7
cpf8

ʻO ka laina Packaging ʻōmole ʻo Taiwan CVC

cpf9
cpf10

ʻO ka laina Packaging Papa CAM Italia

cpf11

Mīkini Pīkī Fette Kelemania

cpf12

ʻO Iapana Viswill Tablet Detector

cpf14-1

Rumi Nahenahe DCS

HOA HOA

ʻO ke alu like ʻana me ka honua
International cooperation
Hana kūloko
Domestic cooperation

  • Kekahi:
  • Aʻe:

  • Kākau i kāu leka ma aneʻi a hoʻouna iā mākou